KOSPI Closes at 5,780 Range... KOSDAQ Rises 1.58%
KOSPI Sees Net Buying by Individuals and Institutions
Samchundang Pharm Tops KOSDAQ by Market Cap
Oral Insulin Expectations Drive Surge
The KOSPI closed on March 20 up 0.31%, finishing the session in the 5,780 range.
On the 20th, the KOSPI index opened at 5813.35, up 50.13 points from the previous trading day. The status of the domestic stock market was displayed on the electronic board in the dealing room of the Hana Bank headquarters in Jung-gu, Seoul. Photo by Kang Jinhyung
View original imageThe KOSPI ended at 5,781.20, up 17.98 points (0.31%) from the previous session. Individual investors and institutions were net buyers of 2.2286 trillion won and 405.4 billion won, respectively, while foreign investors were net sellers of 2.6715 trillion won.
By sector, construction (6.59%), textiles & apparel (3.59%), retail (3.24%), securities (3.03%), and general services (2.99%) showed strong gains. In contrast, transportation equipment & parts (-1.69%) and entertainment & culture (-1.65%) sectors weakened.
Among large-cap stocks, Samsung Electronics (-0.55%), SK hynix (-0.59%), Hyundai Motor (-0.96%), and SK Square (-0.49%) declined, while LG Energy Solution (1.21%) and Samsung Biologics (1.01%) rose.
The KOSDAQ index closed at 1,161.52, up 18.04 points (1.58%). Foreign investors were net buyers of 218.6 billion won, while individuals and institutions were net sellers of 101.1 billion won and 92.4 billion won, respectively.
By sector, most saw gains, with metals (6.68%), transportation & storage (6.11%), pharmaceuticals (4.19%), construction (3.96%), and non-metals (2.60%) performing particularly well.
Among the top market cap stocks, Samchundang Pharm rose 14.09% and Ecopro BM gained 1.16%. In contrast, Ecopro fell 0.13%, Alteogen dropped 1.81%, and Rainbow Robotics plunged 8.22%.
Samchundang Pharm overtook Ecopro to become the largest company by market capitalization on the KOSDAQ market that day. Its market cap reached 21.2759 trillion won, surpassing Ecopro, which had long held the top spot. This surge is attributed to expectations surrounding Samchundang Pharm's development of oral insulin.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Previously, Samchundang Pharm announced the completion of its submission of an Investigational New Drug (IND) application for a Phase 1/2 clinical trial of oral insulin in Europe. Hyeju Wi, a researcher at Korea Investment & Securities, commented, "The clinical results are expected to be available by the end of the year. If successful, Samchundang Pharm would be close to becoming the world's first to develop oral insulin, positioning itself as a game changer in the market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.